Article
Gene Expression Profiles Differentiating Between Breast Cancers Clinically Responsive or Resistant to Letrozole
18 Feb 2009
Abstract excerpt
PURPOSE: Endocrine agents, such as letrozole, are established in the treatment of hormone-dependent breast cancer. However, response rates are only 50% to 70% in the neoadjuvant setting and lower in advanced disease. Thus there is a need to identify novel markers predicting for response and to understand molecular mechanisms of resistance. PATIENTS AND METHODS: Sequential tumor biopsies were taken before and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.